Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v3.4.0.3
Segments (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue $ 3,782,680 $ 1,835,422 $ 10,300,000
Lymphoseek license revenue 254,050 83,333  
Grant and other revenue 685,825 189,701  
Total revenue 4,722,555 2,108,456  
Cost of goods sold, excluding depreciation and amortization 494,639 420,551  
Research and development expenses, excluding depreciation and amortization 2,659,520 3,976,738  
Selling, general and administrative expenses, excluding depreciation and amortization 3,987,358 5,377,402  
Depreciation and amortization 149,592 149,822  
Loss from operations (2,568,554) (7,816,057)  
Other income (expense), excluding equity in the loss of R-NAV, LLC (1,105,456) 787,059  
Equity in the loss of R-NAV, LLC (12,239) (262,227)  
Net loss (3,686,249) (7,291,225)  
Total assets, net of depreciation and amortization 12,283,681   $ 14,964,513
Payments to Acquire Property, Plant, and Equipment 1,847    
Corporate [Member]      
Segment Reporting Information [Line Items]      
Selling, general and administrative expenses, excluding depreciation and amortization 2,975,850 3,320,861  
Depreciation and amortization 109,302 116,766  
Loss from operations (3,085,152) (3,437,627)  
Other income (expense), excluding equity in the loss of R-NAV, LLC (1,105,456) 787,059  
Equity in the loss of R-NAV, LLC (12,239) (262,227)  
Net loss (4,202,847) (2,912,795)  
Payments to Acquire Property, Plant, and Equipment 1,847    
United States [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 3,771,420 1,831,022  
Total assets, net of depreciation and amortization 11,901,094 10,418,933  
United States [Member] | Corporate [Member]      
Segment Reporting Information [Line Items]      
Total assets, net of depreciation and amortization 7,774,939 7,077,673  
International [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 11,260 4,400  
Total assets, net of depreciation and amortization 382,587 498,976  
International [Member] | Corporate [Member]      
Segment Reporting Information [Line Items]      
Total assets, net of depreciation and amortization 1,605 2,665  
Diagnostics [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek license revenue 254,050 83,333  
Grant and other revenue 685,825 189,701  
Total revenue 4,722,555 2,108,456  
Cost of goods sold, excluding depreciation and amortization 494,639 420,551  
Research and development expenses, excluding depreciation and amortization 2,417,720 3,890,724  
Selling, general and administrative expenses, excluding depreciation and amortization 1,012,106 2,042,175  
Depreciation and amortization 40,290 33,056  
Loss from operations 757,800 (4,278,050)  
Net loss 757,800 (4,278,050)  
Diagnostics [Member] | United States [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 3,771,420 1,831,022  
Total assets, net of depreciation and amortization 4,109,640 3,333,851  
Diagnostics [Member] | International [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 11,260 4,400  
Total assets, net of depreciation and amortization 380,982 496,311  
Therapeutics [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Research and development expenses, excluding depreciation and amortization 241,800 86,014  
Selling, general and administrative expenses, excluding depreciation and amortization (598) 14,366  
Loss from operations (241,202) (100,380)  
Net loss (241,202) (100,380)  
Therapeutics [Member] | United States [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Total assets, net of depreciation and amortization $ 16,515 $ 7,409